

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/758,867	01/11/2001	Joseph Kevin Gogerty	1328	1328 9583	
27142	7590 10/03/2003		EXAMINER		
MCKEE, VOORHEES & SEASE, P.L.C. ATTN: PIONEER HI-BRED			FOX, DAVID T		
	REER HI-BRED AVENUE, SUITE 3200		ART UNIT	PAPER NUMBER	
DES MOINE	S, IA 50309-2721		1638		
			DATE MAILED: 10/03/2003	3	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
. Advisory Action	09/758,867	GOGERTY, JOSEP	H KEVIN			
nance, none.	Examiner	Art Unit				
	David T. Fox	1638				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED 27 August 2003 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applice i) a timely filed amendment whi	cation. A proper rep ch places the applic	oly to a cation in			
PERIOD FOR RE	PLY [check either a) or b)]					
a) The period for reply expires 3_months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mo	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THE te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the statutory period for reply originally set in	f the final rejection. E FINAL REJECTION. S 36(a) and the appropriate fee. The appropriate ext the final Office action; or	See MPEP e extension fee tension fee under (2) as set forth in			
earned patent term adjustment. See 37 CFR 1.704(b). 1. A Notice of Appeal was filed on Appellant's			may reduce any			
37 CFR 1.192(a), or any extension thereof (37 CF						
$2. \boxtimes$ The proposed amendment(s) will not be entered be	ecause:					
(a) 🗵 they raise new issues that would require further	er consideration and/or search (see NOTE below);				
(b) they raise the issue of new matter (see Note below);						
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) 🔲 they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: <u>See Continuation Sheet</u> .						
3. Applicant's reply has overcome the following reject	, ,					
4. Newly proposed or amended claim(s) <u>58-61,63-71 and 73-80</u> would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5.⊠ The a) affidavit, b) exhibit, or c) request fo application in condition for allowance because: it r			OT place the			
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which we	re newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: 1,58-61,63-71 and 73-80.						
Claim(s) objected to:						
Claim(s) rejected: <u>62,72,81-87</u> .						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is	a) approved or b) disapp	proved by the Exam	niner.			
9. Note the attached Information Disclosure Stateme	nt(s)(PTO-1449) Paper No(s)	•				
10. Other:						

 Continuation She t (PTOL-303) 09/758,867

Application No.

Continuation of 2. NOTE: New issues: amendment does not comply with revised 37 CFR 1.121 because it does not indicate the status of all of the originally filed claims, namely claims 3,11-14,17-20,22,30-36 and 44-49. Furthermore, a new 112 second paragraph issue is raised by claims 81-82 and 86-87 re "a 5% significance level" which implies that there is more than one 5% significance level. Claim 62 is indefinite in its recitation of "the tissue culture" which lacks antecedent basis in claim 58. The claim should depend upon claim 60. Claim 72 is also indefinite in its recitation of "transgene comprises a transgene encoding" which is awkward. Claim 86 is indefinite in its recitation of "introduced modified... metabolism" which is awkward. The claim also raises enablement issues regarding the introduction of a metabolic pathway.

DAVID T. FOX
PRIMARY EXAMINER
GROUP 180/638